Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 6/20 | 0.52 |
| ▸ | MAPKAPK5 | Q8IW41 | 7/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | TTK | P33981 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22125155 | 1.00 | PTK6 (0.52) | PTK6MAPKAPK5AURKBLCKCNR1 | |
| SCHEMBL30171606 | 0.91 | PTK6 (0.53) | PTK6MAPKAPK5AURKBLCKTTK | |
| SCHEMBL22124498 | 0.91 | PTK6 (0.53) | PTK6MAPKAPK5AURKBLCKTTK | |
| SCHEMBL22124013 | 0.90 | PTK6 (0.52) | PTK6MAPKAPK5AURKBLCKTTK | |
| SCHEMBL22125250 | 0.89 | MAPKAPK5 (0.59) | PTK6MAPKAPK5AURKBLCKAURKA | |
| SCHEMBL30171615 | 0.88 | PTK6 (0.56) | PTK6MAPKAPK5AURKBLCKAURKA | |
| SCHEMBL22124249 | 0.88 | PTK6 (0.56) | PTK6MAPKAPK5AURKBLCKAURKA | |
| SCHEMBL30177817 | 0.88 | PTK6 (0.50) | PTK6MAPKAPK5AURKBLCKTTK | |
| SCHEMBL22125040 | 0.88 | PTK6 (0.50) | PTK6MAPKAPK5AURKBLCKTTK | |
| SCHEMBL22124574 | 0.88 | PTK6 (0.53) | PTK6MAPKAPK5AURKBLCKTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2201/4885MAPKAPK5 728/4885AURKB 3265/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2141/4885MAPKAPK5 695/4885AURKB 3352/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | PTK6 1818/4885MAPKAPK5 516/4885AURKB 3169/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | PTK6 2211/4885MAPKAPK5 647/4885AURKB 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.